What the DOJ’s shortened FCA review timeline means for healthcare and life sciences organizations
A new memorandum compresses FCA reviews from years to months, leaving organizations far less runway to investigate, respond to, and comply with DOJ inquiries.
Written by a human
In brief:
- The DOJ memorandum directs attorneys to complete initial reviews of public benefits qui tam suits within 60 days of filing, a process that typically stretches on for years
- The DOJ now expects whistleblowers (or “relators”) to litigate most of these suits themselves, while the department concentrates on the largest and most complex fraud schemes
- For organizations like pharmaceutical manufacturers, a compressed pre-intervention window means substantially less time to conduct internal investigations, prepare defenses, or negotiate settlements
On May 27, 2026, the Department of Justice (DOJ) issued a memorandum directing its attorneys to fast-track reviews of False Claims Act (FCA) suits alleging fraud against federally funded, state-administered benefits programs.
The FCA is the government’s most powerful anti-fraud tool, and most FCA cases begin as “qui tam” actions—suits filed under seal by private whistleblowers, known as relators, who receive a share of any recovery. The DOJ must review every qui tam complaint and decide whether to intervene, hand the case to the relator, or dismiss it.
Medicaid and the Children’s Health Insurance Program (CHIP) fall under the memo’s remit, but Medicare does not. How the DOJ treats cases implicating both Medicare and Medicaid claims, which dominate healthcare FCA enforcement, remains unclear. However, it’s safe to assume any case touching a state-administered federal funding stream is now on the accelerated track.
The memorandum, which follows a March executive order establishing a task force on benefits fraud, will increase the strain on in-house legal and compliance teams in several ways.
Three significant changes
The DOJ memorandum brings three significant changes to investigation protocols that can impact healthcare and life sciences organizations.
- Significantly reduces the timeframe for pre-intervention decision-making
- Instructs DOJ attorneys to use more aggressive investigation tools and strategies
- Encourages relator management of FCA suits, as opposed to the DOJ taking them on itself
Historically, the under-seal investigation period has given companies ample time to get their house in order before a case goes public. Now, organizations are under much higher pressure to respond to investigations on the department’s timeline.
1: Investigations shortened from years to months
Under the FCA, when a whistleblower files a qui tam complaint, the suit sits under seal while the DOJ investigates and decides whether to intervene. The statute technically gives the department 60 days to make that call, but in practice, courts have granted extension after extension—and investigations routinely drag on for years.
The new memorandum ends that practice for public benefits cases. DOJ attorneys must now complete their initial review within 60 days of filing, extendable to no more than 120. At that point, the department has three options: decline intervention and let the relator proceed, open a further investigation, or move to dismiss the case outright.
Even when the DOJ opts for a deeper investigation, the clock keeps running. Extended investigations must wrap within another 120 days, and any extension beyond that requires sign-off from DOJ leadership.
2: Aggressive tactics employed from the start
To hit these deadlines, the memorandum also instructs attorneys to get aggressive early. Those methods include conducting witness interviews and oral examinations at the outset of an investigation rather than the end, filing enforcement actions when companies are slow to respond to subpoenas and civil investigative demands, and enlisting relator’s counsel to assist with the investigation itself.
3: Most cases will be given over to relators
The memorandum makes clear that the DOJ expects to decline intervention in most public benefits suits, emphasizing cases with less than $10 million in potential damages and non-novel schemes. Relators will need to shoulder the litigation of these cases while the department reserves its resources for the largest, most complex, and most harmful schemes.
The DOJ laid out criteria for the cases it expects relators to run with:
- complaints that satisfy pleading requirements
- allegations corroborated by data analytics or insider information
- schemes that aren’t novel or complex
- potential damages under $10 million
- presence of aggravating factors like beneficiary harm or concealment by the defendant
Relators and their counsel—already responsible for initiating the vast majority of FCA actions—now have a clearer path to litigating them, with the DOJ’s blessing.
What does this mean for healthcare and pharmaceutical organizations?
FCA claims against the industry—whether tied to drug pricing, kickbacks, off-label marketing, or speaker program misconduct—almost always run through federally funded programs like Medicaid.
Previously, pharma manufacturers and healthcare providers facing an FCA investigation had time to conduct a thorough internal investigation, assemble a defense, and negotiate a pre-intervention settlement quietly.
Under the new protocol, that leeway shrinks to a matter of months, and with the DOJ frontloading witness interviews and enforcing subpoenas against slow responders, companies that can’t produce records quickly will find themselves playing defense on the department’s schedule.
Relator-litigated suits also bring more dangers in the form of stronger financial incentives and fewer institutional checks. Allegations that the DOJ might once have investigated (and potentially dismissed) could now proceed straight to litigation instead.
Additionally, the Civil Division’s FCA cooperation credit, which provides incentives to companies that meaningfully cooperate with law enforcement and make good-faith efforts to rectify misconduct, won’t apply to relator-led litigation. Instead, a relator litigating a declined case is chasing treble damages with no obligation to discount for the defendant’s cooperation.
How can compliance teams respond?
The DOJ has made its position clear: investigations will move fast, and companies that move slowly will pay for it. The question for compliance leaders is whether their data infrastructure can keep pace.
If the DOJ must complete an investigation in 120 days, compliance teams need to be able to respond in far less. That means knowing where your communications data lives, being able to search it on demand, and surfacing potential misconduct before a relator does.
Organizations best prepared for this new enforcement tempo are those that treat readiness as a standing posture rather than a crisis response. That looks like:
- complete capture of business communications across every high-risk channel
- a unified archive that legal can search in hours rather than weeks
- proactive monitoring that flags conduct risks while there’s still time to act
Global Relay’s communications monitoring and eDiscovery solutions help companies capture, monitor, and retrieve business communications at speed. Upgrade your compliance program to surface and remediate misconduct before it becomes a federal complaint. Learn more about Global Relay for Healthcare & Life Sciences.
